Portal hypertension is a disorder in which pressure in portal vein and tributaries is increased and portal pressure gradient is more than 10 mmHg. The portal pressure gradient predicts the decompensation of cirrhosis, hepatocellular carcinoma, and development of varices. The development of gastroesophageal varices, one of the consequences of portal hypertension, can cause variceal haemorrhage. There are three types of portal hypertension, including intrahepatic, post-hepatic and pre-hepatic. Portal hypertension is one of the complications of the liver disease. Aga Khan University is in the process of developing carvedilol as a non-selective beta-adrenergic receptor blocker (β1, β2) and an alpha-adrenergic receptor blocker (α1), for the treatment of portal hypertension. Ferring Pharmaceuticals, Inc. is in the process of developing FE 204205 as a vasopressin 1a receptor agonist for the treatment of portal hypertension. Some companies and universities having the pipeline of portal hypertension include Ferring Pharmaceuticals, Inc., Cumberland Pharmaceuticals, Inc., and others.
The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials. Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.